📊 EMMA Key Takeaways
Is EMMA a Good Investment? Thesis Analysis
Emmaus Life Sciences faces severe financial distress with negative stockholders' equity of -$59.5M, indicating the company is technically insolvent. The company is burning cash at an alarming rate (-$2.2M operating cash flow) while revenue has collapsed 43.7% year-over-year, and with only $293K in cash against $29.1M in long-term debt, insolvency risk is critical.
Why Buy EMMA? Key Strengths
- Exceptional gross margin of 92.8% demonstrates strong pricing power on products that generate sales
- Minimal capital expenditure requirements ($1K) suggests asset-light business model
- High gross profit of $8M on available revenue shows operational efficiency at production level
EMMA Investment Risks to Consider
- Negative stockholders' equity of -$59.5M represents technical insolvency and likely covenant violations
- Catastrophic liquidity crisis with current ratio of 0.07x and only $293K cash against $80.2M total liabilities
- Revenue decline of 43.7% YoY combined with negative net margin of -64.4% indicates deteriorating market position and inability to cover operating costs
- Negative operating cash flow of -$2.2M and negative interest coverage ratio of -0.1x indicate inability to service debt obligations
- Zero insider trading activity in past 90 days may suggest lack of management confidence
Key Metrics to Watch
- Cash runway and monthly burn rate relative to remaining cash balance
- Debt restructuring negotiations or covenant amendment discussions
- Revenue stabilization or further decline trends
- Operating cash flow trajectory toward positive territory
- Equity infusion or financing announcements to address insolvency
EMMA Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
EMMA Profitability Ratios
EMMA vs Healthcare Sector
How Emmaus Life Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is EMMA Overvalued or Undervalued?
Based on fundamental analysis, Emmaus Life Sciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
EMMA Balance Sheet & Liquidity
EMMA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Emmaus Life Sciences, Inc.'s revenue has grown significantly by 28% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.07 indicates the company is currently unprofitable.
EMMA Growth Metrics (YoY)
EMMA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.4M | -$1.1M | $0.03 |
| Q2 2025 | $2.8M | -$1.1M | $-0.02 |
| Q1 2025 | $2.4M | -$2.3M | $-0.04 |
| Q3 2024 | $5.0M | $67.0K | $-0.01 |
| Q2 2024 | $5.4M | -$1.6M | $-0.03 |
| Q1 2024 | $2.5M | -$3.5M | $-0.07 |
| Q3 2023 | $4.9M | $67.0K | $-0.01 |
| Q2 2023 | $4.3M | -$1.5M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EMMA Capital Allocation
EMMA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Emmaus Life Sciences, Inc. (CIK: 0000822370)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EMMA
What is the AI rating for EMMA?
Emmaus Life Sciences, Inc. (EMMA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are EMMA's key strengths?
Claude: Exceptional gross margin of 92.8% demonstrates strong pricing power on products that generate sales. Minimal capital expenditure requirements ($1K) suggests asset-light business model.
What are the risks of investing in EMMA?
Claude: Negative stockholders' equity of -$59.5M represents technical insolvency and likely covenant violations. Catastrophic liquidity crisis with current ratio of 0.07x and only $293K cash against $80.2M total liabilities.
What is EMMA's revenue and growth?
Emmaus Life Sciences, Inc. reported revenue of $8.6M.
Does EMMA pay dividends?
Emmaus Life Sciences, Inc. does not currently pay dividends.
Where can I find EMMA SEC filings?
Official SEC filings for Emmaus Life Sciences, Inc. (CIK: 0000822370) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EMMA's EPS?
Emmaus Life Sciences, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EMMA a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Emmaus Life Sciences, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EMMA stock overvalued or undervalued?
Valuation metrics for EMMA: ROE of N/A (sector avg: 15%), net margin of -64.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EMMA stock in 2026?
Our dual AI analysis gives Emmaus Life Sciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EMMA's free cash flow?
Emmaus Life Sciences, Inc.'s operating cash flow is $-2.2M, with capital expenditures of $1.0K. FCF margin is -25.8%.
How does EMMA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -64.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.07 (avg: 2).